uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
[11C]-PIB imaging in patients with Parkinson's disease: preliminary results
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2008 (English)In: Parkinsonism & Related Disorders, ISSN 1353-8020, E-ISSN 1873-5126, Vol. 14, no 4, 345-347 p.Article in journal (Refereed) Published
Abstract [en]

[11C]-PIB positron emission tomography ([11C]-PIB PET) is a sensitive marker of amyloid in Alzheimer's disease (AD), but its specificity has not been fully evaluated. Vascular amyloid-β deposition is common in Parkinson's disease (PD) and α-synuclein, the major component of the Lewy bodies in PD, forms amyloid fibrils. We investigated five apparently cognitively normal PD patients with [11C]-PIB PET. The results were compared to 16 patients with AD and six healthy controls from a previous study. [11C]-PIB retention was not significantly increased in our patients who all had early stage PD. Further studies of more advanced PD patients are warranted.

Place, publisher, year, edition, pages
2008. Vol. 14, no 4, 345-347 p.
Keyword [en]
Parkinson's disease, PET, PIB, Amyloid, Lewy bodies, α-Synuclein
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-16636DOI: 10.1016/j.parkreldis.2007.07.010ISI: 000257646500015OAI: oai:DiVA.org:uu-16636DiVA: diva2:44407
Available from: 2008-05-30 Created: 2008-05-30 Last updated: 2017-12-08Bibliographically approved
In thesis
1. Search for Biomarkers in ALS and Parkinson's Disease: Positron Emission Tomography and Cerebrospinal Fluid Studies
Open this publication in new window or tab >>Search for Biomarkers in ALS and Parkinson's Disease: Positron Emission Tomography and Cerebrospinal Fluid Studies
2009 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

New biomarkers are needed to improve knowledge about pathophysiology, in order to provide earlier correct diagnosis and to follow disease progression of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The aim of this thesis was to find new biomarkers for these diseases.

First, increased serum levels and unchanged levels in postmortal spinal cord of vascular endothelial growth factor (VEGF) were demonstrated. VEGF was not detected in cerebrospinal fluid (CSF) in ALS. Second, increased levels of fibroblast growth factor 2 were found in the CSF and serum of ALS patients. Both studies used enzyme-linked immunoassays. Third, a proteomics method for CSF analysis was explored, based on tryptic digestion and subsequent separation and detection of the peptides by on-line liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. ALS-specific patterns were observed. Four out of five samples were correctly assigned, but no single protein biomarker could be identified. Fourth, [11C](L)-deprenyl-D2 (DED) positron emission tomography (PET) demonstrated increased retention in the pons and white matter in ALS. DED binds to monoamino oxidase B, which in the brain is primarily located in astrocytes. Thus evidence was provided that astrocytosis may be detected in vivo in ALS.

Fifth, normal [11C]-PIB binding in five nondemented patients with PD was reported, in contrast to previous findings of increased retention in Alzheimer's disease reflecting amyloid aggregation. Finally, the combined use of fluorodeoxyglucose and L-[β 11C]-DOPA PET for the differential diagnosis of parkinsonian syndromes was evaluated. PET provided support for the clinical diagnosis in 62 out of 75 patients, and served to exclude suspected diagnoses in another five patients.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2009. 86 p.
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 462
Series
Keyword
amyotrophic lateral sclerosis, ALS, Parkinson’s disease, cerebrospinal fluid, positron emission tomography, vascular endothelial growth factor, fibroblast growth factor 2, proteomics, Fourier transform ion cyclotron resonance mass spectrometry, deprenyl-D2, PIB, FDG, L-[β11C]-DOPA
National Category
Neurology
Research subject
Neurology
Identifiers
urn:nbn:se:uu:diva-102040 (URN)978-91-554-7544-4 (ISBN)
Public defence
2009-06-13, Grönwallsalen, Ingång 70 bv, Akademiska sjukhuset, Uppsala, 13:15 (Swedish)
Opponent
Supervisors
Available from: 2009-05-20 Created: 2009-04-29 Last updated: 2009-05-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Johansson, AndersForsberg, AndersEngler, HenryLångström, BengtAskmark, Håkan

Search in DiVA

By author/editor
Johansson, AndersForsberg, AndersEngler, HenryLångström, BengtAskmark, Håkan
By organisation
NeurologyDepartment of Medical Sciences
In the same journal
Parkinsonism & Related Disorders
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 394 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf